International Stem Cell(ISCO)
SAN DIEGO, CABiotechnology
Focus: International Stem Cell is a publicly traded biotechnology company focused on proprietary stem cell induction technology and cell therapy applications, operating at modest commercial scale with $9M in FY 2025 revenue.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
1+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at International Stem Cell?
AI assessmentInternational Stem Cell presents high execution risk due to cash depletion, unclear strategic focus, and absence of hiring activity; suitable only for risk-tolerant candidates seeking exposure to stem cell science without near-term growth prospects.
Why Work Here
- Exposure to emerging stem cell induction technology, a differentiated platform with potential to address multiple therapeutic areas including ophthalmology and neurology.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$9M
Pipeline & Clinical Trials
High frequency pure tone audiometry
Hearing Loss, SensorineuralClinical Trials (1)
NCT04270916Prevalence and Impact on QoL From Ototoxicity in Cancer Survivors
N/AHelp build intelligence for International Stem Cell
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.